1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts. Issue 2 (December 2016) Authors: Althammer, Sonja; Steele, Keith; Rebelatto, Marlon; Tan, Tze; Wiestler, Tobias; Schmidt, Guenter; Higgs, Brandon; Li, Xia; Shi, Li; Jin, Xiaoping; Antal, Joyce; Gupta, Ashok; Ranade, Koustubh; Binning, Gerd; Bellmunt, Joaquim; de Wit, Ronald; Vaughn, David; Fradet, Yves; Lee, Jae; Fong, Lawrence Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 2(2016) Page Start: 223 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts. Issue 2 (December 2016) Authors: Althammer, Sonja; Steele, Keith; Rebelatto, Marlon; Tan, Tze; Wiestler, Tobias; Schmidt, Guenter; Higgs, Brandon; Li, Xia; Shi, Li; Jin, Xiaoping; Antal, Joyce; Gupta, Ashok; Ranade, Koustubh; Binning, Gerd; Bellmunt, Joaquim; de Wit, Ronald; Vaughn, David; Fradet, Yves; Lee, Jae; Fong, Lawrence Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 2(2016) Page Start: 223 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016. (8th December 2016) Authors: Althammer, Sonja; Steele, Keith; Rebelatto, Marlon; Tan, Tze Heng; Wiestler, Tobias; Schmidt, Guenter; Higgs, Brandon; Li, Xia; Shi, Li; Jin, Xiaoping; Antal, Joyce; Gupta, Ashok; Ranade, Koustubh; Binning, Gerd; Bellmunt, Joaquim; de Wit, Ronald; Vaughn, David J.; Fradet, Yves; Lee, Jae Lyun; Fo... Journal: Journal for immunotherapy of cancer Issue: Volume 4(2016)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 682 Antibody-mediated blockade of interleukin-10 receptor-alpha promotes the activation of immune cells from in vitro dissociated tumor samples. (10th December 2020) Authors: Berezhnoy, Alexey; Shah, Kalpana; Liu, Daorong; Lung, Peter; Long, Vatana; Stahl, Kurt; Smith, Douglas; Chen, Francine; Li, Hua; Li, Jonathan; Alderson, Ralph; Ciccarone, Valentina; Tamura, James; Bonvini, Ezio; Diedrich, Gundo; Moore, Paul Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 682 Antibody-mediated blockade of interleukin-10 receptor-alpha promotes the activation of immune cells from in vitro dissociated tumor samples. (9th November 2020) Authors: Berezhnoy, Alexey; Shah, Kalpana; Liu, Daorong; Lung, Peter; Long, Vatana; Stahl, Kurt; Smith, Douglas; Chen, Francine; Li, Hua; Li, Jonathan; Alderson, Ralph; Ciccarone, Valentina; Tamura, James; Bonvini, Ezio; Diedrich, Gundo; Moore, Paul Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). (6th November 2014) Authors: Uy, Geoffrey; Stewart, Stanford; Baughman, Jan; Rettig, Michael; Chichili, Gurunadh; Bonvini, Ezio; Wigginton, Jon; Lechleider, Robert; DiPersio, John Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma. (6th November 2014) Authors: Hurwitz, Herbert; Crocenzi, Todd; Lohr, Joanna; Bonvini, Ezio; Johnson, Syd; Moore, Paul; Wigginton, Jon Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer. Issue 2 (December 2015) Authors: Urba, Walter; Chmielowski, Bartosz; Loo, Deryk; Baughman, Jan; Chen, Francine; Moore, Paul; Bonvini, Ezio; Vasselli, James; Wigginton, Jon; Rizvi, Naiyer Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer. (4th November 2015) Authors: Urba, Walter; Chmielowski, Bartosz; Loo, Deryk; Baughman, Jan; Chen, Francine; Moore, Paul; Bonvini, Ezio; Vasselli, James; Wigginton, Jon; Rizvi, Naiyer Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer. Issue 2 (December 2015) Authors: Baughman, Jan; Loo, Deryk; Chen, Francine; Moore, Paul; Bonvini, Ezio; Vasselli, James; Wigginton, Jon; Cohen, Roger Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗